• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲型流感 M2 通道 V27A 耐药突变体的溶液 NMR 结构。

Solution NMR structure of the V27A drug resistant mutant of influenza A M2 channel.

机构信息

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.

出版信息

Biochem Biophys Res Commun. 2010 Oct 8;401(1):58-63. doi: 10.1016/j.bbrc.2010.09.008. Epub 2010 Sep 15.

DOI:10.1016/j.bbrc.2010.09.008
PMID:20833142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3215091/
Abstract

The M2 protein of influenza A virus forms a proton-selective channel that is required for viral replication. It is the target of the anti-influenza drugs, amantadine and rimantadine. Widespread drug resistant mutants, however, has greatly compromised the effectiveness of these drugs. Here, we report the solution NMR structure of the highly pathogenic, drug resistant mutant V27A. The structure reveals subtle structural differences from wildtype that maybe linked to drug resistance. The V27A mutation significantly decreases hydrophobic packing between the N-terminal ends of the transmembrane helices, which explains the looser, more dynamic tetrameric assembly. The weakened channel assembly can resist drug binding either by destabilizing the rimantadine-binding pocket at Asp44, in the case of the allosteric inhibition model, or by reducing hydrophobic contacts with amantadine in the pore, in the case of the pore-blocking model. Moreover, the V27A structure shows a substantially increased channel opening at the N-terminal end, which may explain the faster proton conduction observed for this mutant. Furthermore, due to the high quality NMR data recorded for the V27A mutant, we were able to determine the structured region connecting the channel domain to the C-terminal amphipathic helices that was not determined in the wildtype structure. The new structural data show that the amphipathic helices are packed much more closely to the channel domain and provide new insights into the proton transfer pathway.

摘要

甲型流感病毒的 M2 蛋白形成一个质子选择性通道,该通道是病毒复制所必需的。它是抗流感药物金刚烷胺和金刚乙胺的作用靶点。然而,广泛存在的耐药突变体大大降低了这些药物的有效性。在这里,我们报告了高度致病性、耐药突变体 V27A 的溶液 NMR 结构。该结构揭示了与耐药性相关的野生型细微结构差异。V27A 突变显著降低了跨膜螺旋 N 端之间的疏水性堆积,这解释了更松散、更动态的四聚体组装。减弱的通道组装可以通过破坏别构抑制模型中 Asp44 处的金刚烷胺结合口袋,或者通过减少孔中与金刚烷胺的疏水性接触,从而抵抗药物结合,在孔阻塞模型中也是如此。此外,V27A 结构显示 N 端的通道开口大大增加,这可能解释了该突变体观察到的更快质子传导。此外,由于为 V27A 突变体记录了高质量的 NMR 数据,我们能够确定连接通道域和 C 端两亲性螺旋的结构区域,而在野生型结构中未确定该区域。新的结构数据表明,两亲性螺旋与通道域的包装更加紧密,并为质子转移途径提供了新的见解。

相似文献

1
Solution NMR structure of the V27A drug resistant mutant of influenza A M2 channel.甲型流感 M2 通道 V27A 耐药突变体的溶液 NMR 结构。
Biochem Biophys Res Commun. 2010 Oct 8;401(1):58-63. doi: 10.1016/j.bbrc.2010.09.008. Epub 2010 Sep 15.
2
Structure and mechanism of the M2 proton channel of influenza A virus.甲型流感病毒M2质子通道的结构与机制
Nature. 2008 Jan 31;451(7178):591-5. doi: 10.1038/nature06531.
3
X-ray Crystal Structures of the Influenza M2 Proton Channel Drug-Resistant V27A Mutant Bound to a Spiro-Adamantyl Amine Inhibitor Reveal the Mechanism of Adamantane Resistance.流感 M2 质子通道耐药 V27A 突变体与金刚烷胺类 Spiro-Adamantyl 胺抑制剂结合的 X 射线晶体结构揭示了金刚烷类耐药的机制。
Biochemistry. 2020 Feb 4;59(4):627-634. doi: 10.1021/acs.biochem.9b00971. Epub 2020 Jan 13.
4
Structural comparison of the wild-type and drug-resistant mutants of the influenza A M2 proton channel by molecular dynamics simulations.通过分子动力学模拟对流感 A M2 质子通道的野生型和耐药突变体的结构比较。
J Phys Chem B. 2013 May 23;117(20):6042-51. doi: 10.1021/jp312396q. Epub 2013 May 9.
5
An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.一种M2-V27A通道阻滞剂对金刚烷胺敏感和耐药的甲型流感病毒均表现出强大的体外和体内抗病毒活性。
Antiviral Res. 2017 Apr;140:45-54. doi: 10.1016/j.antiviral.2017.01.006. Epub 2017 Jan 10.
6
Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus.设计和药理学表征抗金刚烷胺的流感 A 病毒 M2 离子通道突变体抑制剂。
Biochemistry. 2009 Dec 22;48(50):11872-82. doi: 10.1021/bi9014488.
7
Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers.流感 M2 质子通道在脂质双层中的金刚烷胺结合位点的结构。
Nature. 2010 Feb 4;463(7281):689-92. doi: 10.1038/nature08722.
8
Virtual screening and molecular growth guide the design of inhibitors for the influenza virus drug-resistant mutant M2-V27A/S31N.虚拟筛选和分子生长指导设计用于流感病毒耐药突变体 M2-V27A/S31N 的抑制剂。
J Biomol Struct Dyn. 2024 Jul;42(10):5253-5267. doi: 10.1080/07391102.2023.2233026. Epub 2023 Jul 9.
9
Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus.甲型流感病毒 M2 离子通道耐药 S31N 突变体的结构与抑制。
Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1315-20. doi: 10.1073/pnas.1216526110. Epub 2013 Jan 9.
10
X-ray Crystal Structure of the Influenza A M2 Proton Channel S31N Mutant in Two Conformational States: An Open and Shut Case.X 射线晶体结构的流感 A M2 质子通道 S31N 突变体在两种构象状态下:开与关的案例。
J Am Chem Soc. 2019 Jul 24;141(29):11481-11488. doi: 10.1021/jacs.9b02196. Epub 2019 Jul 11.

引用本文的文献

1
Molecular biophysics and inhibition mechanism of influenza virus A M2 viroporin by adamantane-based drugs - Challenges in designing antiviral agents.甲型流感病毒M2离子通道蛋白的分子生物物理学及金刚烷类药物的抑制机制——抗病毒药物设计面临的挑战
J Struct Biol X. 2025 Feb 4;11:100122. doi: 10.1016/j.yjsbx.2025.100122. eCollection 2025 Jun.
2
Inhibitors of the small membrane (M) protein viroporin prevent Zika virus infection.小膜(M)蛋白病毒孔道抑制剂可预防寨卡病毒感染。
Elife. 2024 Aug 23;13:e68404. doi: 10.7554/eLife.68404.
3
Real-time tracking of drug binding to influenza A M2 reveals a high energy barrier.甲型流感病毒M2蛋白药物结合的实时追踪揭示了一个高能屏障。
J Struct Biol X. 2023 Jun 7;8:100090. doi: 10.1016/j.yjsbx.2023.100090. eCollection 2023 Dec.
4
Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza.靶向 M2 质子通道抑制剂可增强金刚烷胺耐药大流行性流感的联合治疗作用。
PLoS Pathog. 2020 Aug 11;16(8):e1008716. doi: 10.1371/journal.ppat.1008716. eCollection 2020 Aug.
5
Put a cork in it: Plugging the M2 viral ion channel to sink influenza.塞住它:堵住 M2 病毒离子通道以消灭流感。
Antiviral Res. 2020 Jun;178:104780. doi: 10.1016/j.antiviral.2020.104780. Epub 2020 Mar 27.
6
Observation of the Imidazole-Imidazolium Hydrogen Bonds Responsible for Selective Proton Conductance in the Influenza A M2 Channel.观察咪唑-咪唑鎓氢键在甲型流感 M2 通道中选择性质子传导中的作用。
J Am Chem Soc. 2020 Feb 5;142(5):2115-2119. doi: 10.1021/jacs.9b09985. Epub 2020 Jan 28.
7
Imidazole-Imidazole Hydrogen Bonding in the pH-Sensing Histidine Side Chains of Influenza A M2.流感 A M2 中 pH 感应组氨酸侧链的咪唑-咪唑氢键作用
J Am Chem Soc. 2020 Feb 12;142(6):2704-2708. doi: 10.1021/jacs.9b10984. Epub 2020 Jan 30.
8
X-ray Crystal Structures of the Influenza M2 Proton Channel Drug-Resistant V27A Mutant Bound to a Spiro-Adamantyl Amine Inhibitor Reveal the Mechanism of Adamantane Resistance.流感 M2 质子通道耐药 V27A 突变体与金刚烷胺类 Spiro-Adamantyl 胺抑制剂结合的 X 射线晶体结构揭示了金刚烷类耐药的机制。
Biochemistry. 2020 Feb 4;59(4):627-634. doi: 10.1021/acs.biochem.9b00971. Epub 2020 Jan 13.
9
Beyond Structural Biology to Functional Biology: Solid-State NMR Experiments and Strategies for Understanding the M2 Proton Channel Conductance.从结构生物学到功能生物学:固态 NMR 实验与理解 M2 质子通道电导的策略。
J Phys Chem B. 2017 May 11;121(18):4799-4809. doi: 10.1021/acs.jpcb.7b02468. Epub 2017 May 2.
10
Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.稳扎稳打才能赢:甲型流感病毒野生型和V27A突变体M2通道新型双重抑制剂之间的差异
J Med Chem. 2017 May 11;60(9):3727-3738. doi: 10.1021/acs.jmedchem.6b01758. Epub 2017 Apr 24.

本文引用的文献

1
Three-dimensional triple-resonance NMR Spectroscopy of isotopically enriched proteins. 1990.同位素富集蛋白质的三维三共振核磁共振光谱学。1990年。
J Magn Reson. 2011 Dec;213(2):423-41. doi: 10.1016/j.jmr.2011.09.004.
2
Flu channel drug resistance: a tale of two sites.流感通道药物耐药性:两个位点的故事。
Protein Cell. 2010 Mar;1(3):246-58. doi: 10.1007/s13238-010-0025-y. Epub 2010 Feb 23.
3
Magic angle spinning NMR investigation of influenza A M2(18-60): support for an allosteric mechanism of inhibition.魔角旋转 NMR 研究流感 A M2(18-60):对别构抑制机制的支持。
J Am Chem Soc. 2010 Aug 18;132(32):10958-60. doi: 10.1021/ja101537p.
4
Influenza M2 proton channels.流感M2质子通道
Biochim Biophys Acta. 2011 Feb;1808(2):522-9. doi: 10.1016/j.bbamem.2010.04.015. Epub 2010 May 6.
5
Double (V27A/S31N) mutant 2009 pandemic influenza A (H1N1) virus isolated from adamantane non-treated inmunocompetent child.从未接受金刚烷胺治疗的免疫功能正常的儿童中分离到的 2009 年大流行甲型流感 A(H1N1)病毒的双(V27A/S31N)突变株。
Diagn Microbiol Infect Dis. 2010 May;67(1):114-5. doi: 10.1016/j.diagmicrobio.2009.12.019. Epub 2010 Mar 12.
6
Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers.流感 M2 质子通道在脂质双层中的金刚烷胺结合位点的结构。
Nature. 2010 Feb 4;463(7281):689-92. doi: 10.1038/nature08722.
7
An amantadine-sensitive chimeric BM2 ion channel of influenza B virus has implications for the mechanism of drug inhibition.一种对金刚烷胺敏感的乙型流感病毒嵌合BM2离子通道对药物抑制机制具有启示意义。
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18775-9. doi: 10.1073/pnas.0910584106. Epub 2009 Oct 19.
8
Mechanism of drug inhibition and drug resistance of influenza A M2 channel.甲型流感病毒M2通道的药物抑制机制及耐药性
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7379-84. doi: 10.1073/pnas.0902548106. Epub 2009 Apr 21.
9
Energetic analysis of the two controversial drug binding sites of the M2 proton channel in influenza A virus.甲型流感病毒M2质子通道两个有争议的药物结合位点的能量分析。
J Theor Biol. 2009 Jul 7;259(1):159-64. doi: 10.1016/j.jtbi.2009.03.003. Epub 2009 Mar 12.
10
High prevalence of amantadine resistance among circulating European porcine influenza A viruses.欧洲流行的甲型猪流感病毒中金刚烷胺耐药性普遍存在。
J Gen Virol. 2009 Apr;90(Pt 4):900-908. doi: 10.1099/vir.2008.007260-0. Epub 2009 Feb 17.